







NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

AGENDA 30

Time & Date: 4pm – 4.30 pm Tuesday November 16 2021

Venue: Via Teams

Host: – NPSA Executive Director

Attendees: Symbion Symbion

Sigma Healthcare
National Pharmacies

Apologies: AP

1	Welcome – apologies - Reminder of meeting purpose and conduct as per ACCC temporary authorisation - Review of the previous minutes – refer to Attachment A	EC ALL
2	Trends in supply and demand of medicines - General discussion by all members on trends and observations over the previous month with focus on any new spikes in cases	ALL
3	Specific medicines at risk – NEW - General discussion by all members on any NEW medicines identified or have been placed on a watch list	ALL
4	Specific medicines at risk – EXISTING - General discussion by all members on existing medicines placed on restriction:	ALL
5	Reporting - TGA Reporting - Update on ACCC Authorisation and associated reporting	ALL EC









6.	Other Business - Border closures – any impact on medicine supply	
	- COVID Vaccine Distribution update - RAT Kit supply reporting	ALL EC
		EC









Attachment A

NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

Minutes 29

Time & Date: 4.00 pm - 4.30 pm Tuesday October 29 2021

Venue: Via Teams

Host: **NPSA Executive Director**

Attendees: Symbion Symbion

API NPD

Apologies: Sigma Healthcare

ITEM	DISCUSSION AREA	ACTION AGREED
1	 Welcome meeting purpose and conduct as per ACCC authorisation was discussed. Minutes from the September 2021, meeting accepted 	Noted and accepted Minutes Accepted
2	- All members commented that over the last four weeks there has been no new abnormal demand or signs of concern regarding potential stockpiling behaviour nationally or locally - Members did discuss that the medicines supply chain is moving into a new phase of COVID-19 management as the country "opens up" again	All members to watch ordering behavior closely and report back into the group immediately if they detect any areas of concern as the country "opens up"
3	- Specific medicines at risk – NEW	NPSA to confirm the TGA









		Members to continue to monitor
4	Specific medicines at risk – EXISTING	Noted and actioned
		NPSA to organize ASAP NPSA to email DoH making the request
5	Reporting - Update on TGA Reporting – - Update on ACCC Authorisation – - Members were briefed that an interim extension to our Authorisation has been granted	Noted
5	- Living with COVID – members discussed the next phase of COVID -19 as the country opens up and borders open Members anticipate new demands on the supply chain will occur – members discussed the need to remain vigilant and the value of this forum to collectively share and manage potential issues in supply	All members to watch closely and report back into the group if this becomes an increasing threat to supply









- COVID Vaccine Distribution –	Noted
Next meeting – Tuesday November 16, 2021, 4pm – 5 pm	









NPSA Medicines Shortages CSOD Supply Restriction under COVID-19 Working Group

Minutes 30

Time & Date: 4.00 pm – 4.30 pm Tuesday November 16 2021

Venue: Via Teams

Host: – NPSA Executive Director

Attendees: Symbion Symbion

Sigma Healthcare

NPD

Apologies: API

ITEM	DISCUSSION AREA	ACTION AGREED
1	Welcome - meeting purpose and conduct as per ACCC authorisation was discussed	Noted and accepted
	- Minutes from the October 2021 meeting accepted	Minutes Accepted
2	Trends in supply and demand of medicines All members commented that over the last four weeks there has been no new abnormal demand or signs of concern regarding potential stockpiling behaviour nationally or locally	All members to watch ordering behavior closely and report back into the group immediately if they detect any areas of concern as the country "opens up"
3	 Specific medicines at risk – NEW No new medicines at risk flagged by members 	Noted
4	Specific medicines at risk – EXISTING	









